[Conservative treatment of benign prostatic hypertrophy: reevaluation of the effect of eviprostat by subjective symptoms and uroflowmetry].
The clinical effect of Eviprostat was evaluated in 53 patients with benign prostatic hypertrophy. Subjective symptoms were improved in 86.2% of the patients who were treated with Eviprostat. Nomogram unit of uroflowmetry also improved in 51.4% of the patients. The overall clinical efficacy estimated by the combination of subjective symptoms and uroflowmetry was observed in 90.9% of the patients. In conclusion, Eviprostat was considered to be useful in patients with discomfort symptoms who had no immediate indication for prostatectomy.
D000368:Aged; D001557:Benzenesulfonates / Q000627:therapeutic use*; D004338:Drug Combinations / Q000008:administration & dosage / Q000627:therapeutic use; D004341:Drug Evaluation; D004979:Ethamsylate / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010936:Plant Extracts / Q000008:administration & dosage / Q000627:therapeutic use*; D011470:Prostatic Hyperplasia / Q000188:drug therapy* / Q000503:physiopathology; D014556:Urine; D014563:Urodynamics
D001557:Benzenesulfonates; D004338:Drug Combinations; D010936:Plant Extracts; D004979:Ethamsylate; C010152:eviprostat